620 related articles for article (PubMed ID: 26572704)
41. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.
Kwan SY; Cheng X; Tsang YT; Choi JS; Kwan SY; Izaguirre DI; Kwan HS; Gershenson DM; Wong KK
Oncotarget; 2016 Aug; 7(35):56933-56943. PubMed ID: 27486766
[TBL] [Abstract][Full Text] [Related]
42. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.
Nagymanyoki Z; Mutter GL; Hornick JL; Cibas ES
Cancer Cytopathol; 2015 Apr; 123(4):253-7. PubMed ID: 25557364
[TBL] [Abstract][Full Text] [Related]
43. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.
Guan B; Gao M; Wu CH; Wang TL; Shih IeM
Neoplasia; 2012 Oct; 14(10):986-93. PubMed ID: 23097632
[TBL] [Abstract][Full Text] [Related]
44. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
45. The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.
Toumpeki C; Liberis A; Tsirkas I; Tsirka T; Kalagasidou S; Inagamova L; Anthoulaki X; Tsatsaris G; Kontomanolis EN
In Vivo; 2019; 33(3):659-667. PubMed ID: 31028182
[TBL] [Abstract][Full Text] [Related]
46. Knockdown of mutated ARID1A inhibited endometrial cancer cell proliferation and stimulated cell apoptosis.
Ye Y; Wei B; Xiaowei X
J BUON; 2018; 23(4):1082-1091. PubMed ID: 30358215
[TBL] [Abstract][Full Text] [Related]
47. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
[TBL] [Abstract][Full Text] [Related]
48. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
49. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
50. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
[TBL] [Abstract][Full Text] [Related]
51. Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
De P; Dey N
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731647
[TBL] [Abstract][Full Text] [Related]
52. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
54. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
[TBL] [Abstract][Full Text] [Related]
55. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
56. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.
Guan B; Rahmanto YS; Wu RC; Wang Y; Wang Z; Wang TL; Shih IeM
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24899687
[TBL] [Abstract][Full Text] [Related]
57. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
58. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
[TBL] [Abstract][Full Text] [Related]
59. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.
Liu G; Xu P; Fu Z; Hua X; Liu X; Li W; Zhang M; Wu J; Wen J; Xu J; Jia X
J Cell Biochem; 2017 Dec; 118(12):4517-4525. PubMed ID: 28466574
[TBL] [Abstract][Full Text] [Related]
60. Mass spectrometric analysis of the phosphorylation levels of the SWI/SNF chromatin remodeling/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines.
Kimura A; Arakawa N; Hirano H
J Proteome Res; 2014 Nov; 13(11):4959-69. PubMed ID: 25083560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
